Literature DB >> 17563880

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

Maria Plataki, Katerina Vaporidi, Dimitris Georgopoulos.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17563880     DOI： 10.1007/s00134-007-0707-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  7 in total

1.  Increasing evidence that the risks of rhAPC may outweigh its benefits.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

2.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

3.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Authors:  Jean-Louis Vincent; Gordon R Bernard; Richard Beale; Christopher Doig; Christian Putensen; Jean-Francois Dhainaut; Antonio Artigas; Roberto Fumagalli; William Macias; Theressa Wright; Kar Wong; David P Sundin; Mary Ann Turlo; Jonathan Janes
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

4.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

5.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Authors:  Simon Nadel; Brahm Goldstein; Mark D Williams; Heidi Dalton; Mark Peters; William L Macias; Shamel A Abd-Allah; Howard Levy; Robinette Angle; Dazhe Wang; David P Sundin; Brett Giroir
Journal:  Lancet       Date:  2007-03-10       Impact factor: 79.321

6.  Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Authors:  Salmaan Kanji; Marc M Perreault; Clarence Chant; David Williamson; Lisa Burry
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

7.  Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.

Authors:  Guido Bertolini; Carlotta Rossi; Abramo Anghileri; Sergio Livigni; Antonio Addis; Daniele Poole
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440
  7 in total
  1 in total

Review 1.  The safety profile of drotrecogin alfa (activated).

Authors:  Roberto Fumagalli; Mariano A Mignini
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.